Clinical Trial

Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 4, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, open-label, multicenter, prospective quasi-experimental study evaluating the efficacy and safety of extended-release paliperidone in adults with schizophrenia in Bangladesh. The study will assess psychotic symptom improvement using the PANSS scale, monitor side effects using GASS, and evaluate quality of life via WHOQOL-BREF.
Trial Details
NCT Number NCT07153835
Lead Sponsor Sher-E-Bangla Medical College
Collaborators: ACI Pharmaceuticals, US-Bangla Medical College Hospital, Dr. M M Jalal Uddin, Dr.Ahsan Aziz Sarkar
Conditions Schizophrenia
Enrollment 505 participants
Start Date 2025-09-01
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-04